Search results
There is a page named "Gilteritinib" on Wikipedia
Gilteritinib, sold under the brand name Xospata, is an anti-cancer drug. Gilteritinib acts as an inhibitor of FLT3, hence it is a tyrosine kinase inhibitor...8 KB (511 words) - 17:02, 24 February 2025
TKD mutations. In 2017, gilteritinib gained FDA orphan drug status for AML. In November 2018, the FDA approved gilteritinib (Xospata) for treatment of...15 KB (1,727 words) - 02:27, 15 October 2024
– bactericidal lipoglycopeptide – marketed with Theravance. Xospata (gilteritinib) – AXL receptor tyrosine kinase Xtandi (enzalutamide) – Prostate cancer...27 KB (2,460 words) - 00:25, 13 September 2024
currently testing gilteritinib (ASP2215), a dual FLT3-AXL tyrosine kinase inhibitor in acute myeloid leukemia (AML). In 2017, gilteritinib gained FDA orphan...20 KB (2,438 words) - 20:23, 23 February 2025- Pemigatinib Avapritinib Cabozantinib Capivasertib Capmatinib Entrectinib Gilteritinib Larotrectinib Lenvatinib Masitinib Midostaurin Nintedanib Odronextamab...12 KB (821 words) - 11:51, 17 February 2025
- Pemigatinib Avapritinib Cabozantinib Capivasertib Capmatinib Entrectinib Gilteritinib Larotrectinib Lenvatinib Masitinib Midostaurin Nintedanib Odronextamab...12 KB (758 words) - 23:46, 14 March 2024
- L01EX10 Midostaurin L01EX11 Quizartinib L01EX12 Larotrectinib L01EX13 Gilteritinib L01EX14 Entrectinib L01EX15 Pexidartinib L01EX17 Capmatinib L01EX18 Avapritinib...13 KB (935 words) - 04:36, 23 December 2024
Jensen RA, McGuirk JP, Balusu R (May 2021). "Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells". Molecular Cancer...42 KB (5,288 words) - 13:09, 4 October 2024
found that two previously described kinase inhibitors, midostaurin and gilteritinib, inhibit the EGFR triple mutant, which was resistant to all known tyrosine...16 KB (1,667 words) - 00:10, 8 January 2025
- gilteritinib (uncountable) A kinase inhibitor used as an anticancer drug